FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 317 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Indications for Durvalumab in the Management of... October 25, 2023 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. May 21, 2019 Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 Load more HOT NEWS Why investing in cancer research is good for the economy Making a startup out of a scientist Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with... El cáncer en mi comunidad: El rol de la detección del...
